MARKET

GLPG

GLPG

Galapagos Nv
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.75
-2.22
-3.83%
Opening 15:00 05/18 EDT
OPEN
57.60
PREV CLOSE
57.97
HIGH
57.80
LOW
55.70
VOLUME
220.01K
TURNOVER
4.49M
52 WEEK HIGH
81.12
52 WEEK LOW
46.41
MARKET CAP
3.66B
P/E (TTM)
-31.6581
1D
5D
1M
3M
1Y
5Y
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks · 2d ago
Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs
Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.
Zacks · 05/11 13:47
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet.
Benzinga · 05/09 19:30
--RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating
MT Newswires · 05/09 07:58
Galapagos creates new subscription right plans
Mechelen, Belgium; 6 May 2022, 22.01 CET; regulated information –– Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 2,326,025 subscription rights under new subscription right plans for the benefit of certain member...
GlobeNewswire · 05/06 20:01
BRIEF-Galapagos Q1 Operating Loss Narrows To EUR 21.1 Million
reuters.com · 05/06 05:52
BRIEF-Galapagos NV - QTRLY Group Revenues +20% To EUR 136.3 Million
reuters.com · 05/05 22:35
Galapagos GAAP EPS of -€0.20, revenue of €136.3M
Galapagos press release (NASDAQ:GLPG): Q1 GAAP EPS of -€0.20. Revenue of €136.3M (+19.7% Y/Y). "For 2022, we anticipate a significantly lower cash burn compared to 2021 of €450M-€490M, including anticipated net
Seekingalpha · 05/05 21:00
More
No Data
Learn about the latest financial forecast of GLPG. Analyze the recent business situations of Galapagos Nv through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
42.86%Buy
57.14%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GLPG stock price target is 73.93 with a high estimate of 100.36 and a low estimate of 61.22.
High100.36
Average73.93
Low61.22
Current 55.75
EPS
Actual
Estimate
-1.21-0.82-0.43-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 174
Institutional Holdings: 12.64M
% Owned: 19.25%
Shares Outstanding: 65.65M
TypeInstitutionsShares
Increased
33
2.04M
New
18
1.27M
Decreased
23
549.77K
Sold Out
14
452.73K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.31%
Pharmaceuticals & Medical Research
-1.90%
Key Executives
Chairman/Chief Executive Officer/Director
Paulus Stoffels
President/Chief Financial Officer/Chief Operating Officer/Management Board
Bart Filius
Management Board
Walid Abi-Saab
Management Board
Andre Hoekema
Management Board
Michele Manto
Non-Executive Director
Linda Higgins
Non-Executive Director
Daniel O' Day
Independent Director
Dan Baker
Independent Director
Jerome Contamine
Non-Executive Independent Director
Katrine Bosley
Non-Executive Independent Director
Peter Guenter
Non-Executive Independent Director
Mary Kerr
Non-Executive Independent Director
Howard Rowe
Non-Executive Independent Director
Elisabeth Svanberg
No Data
No Data
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Webull offers kinds of Galapagos NV stock information, including NASDAQ:GLPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLPG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLPG stock methods without spending real money on the virtual paper trading platform.